Ebolavirus VP35 is a multifunctional virulence factor

References

• Geisbert TW, Hensley LE. Ebola virus: New insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 2004; 6:1 - 24
   PubMedGoogle Scholar
• Sanchez A, Geisbert TW, Feldmann H. Knipe DM, Howley PM, Griffin RA, Martin MA, Roizman B, Straus SE. Filoviridae: Marburg, Ebola Viruses. Fields Virology 2006; Philadenphia, PA Lippincott Williams & Wilkins 1409 - 1448
   Google Scholar
• Mohamadzadeh M, Chen L, Schmaljohn AL. How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol 2007; 7:556 - 567
   PubMed Web of Science ®Google Scholar
• Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 2005; 37:1560 - 1566
   PubMed Web of Science ®Google Scholar
• Bray M, Murphy FA. Filovirus research: knowledge expands to meet a growing threat. J Infect Dis 2007; 196:438 - 443
   Web of Science ®Google Scholar
• Reed DS, Mohamadzadeh M. Status and challenges of filovirus vaccines. Vaccine 2007; 25:1923 - 1934
   PubMed Web of Science ®Google Scholar
• Basler CF, Amarasinghe GK. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res 2009; 29:511 - 520
   PubMed Web of Science ®Google Scholar
• Saito T, Gale M Jr. Principles of intracellular viral recognition. Curr Opin Immunol 2007; 19:17 - 23
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. J Biochem 2007; 141:137 - 145
   PubMed Web of Science ®Google Scholar
• Wilkins C, Gale M Jr. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010; 22:41 - 47
   PubMed Web of Science ®Google Scholar
• Schlee M, Hartmann E, Coch C, Wimmenauer V, Janke M, Barchet W, Hartmann G. Approaching the RNA ligand for RIG-I?. Immunol Rev 2009; 227:66 - 74
   PubMed Web of Science ®Google Scholar
• Schlee M, Hartmann G. The Chase for the RIG-I Ligand-Recent Advances. Mol Ther 2010;
   PubMed Web of Science ®Google Scholar
• Basler CF, Garcia-Sastre A. Viruses and the type I interferon antiviral system: induction and evasion. Int Rev Immunol 2002; 21:305 - 337
   PubMedGoogle Scholar
• Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 2000; 97:12289 - 12294
   PubMed Web of Science ®Google Scholar
• Muhlberger E, Lotfering B, Klenk HD, Becker S. Three of the four nucleocapsid proteins of Marburg virus, NP, VP35 and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J Virol 1998; 72:8756 - 8764
   PubMed Web of Science ®Google Scholar
• Noda T, Aoyama K, Sagara H, Kida H, Kawaoka Y. Nucleocapsid-like structures of Ebola virus reconstructed using electron tomography. J Vet Med Sci 2005; 67:325 - 328
   Google Scholar
• Haasnoot J, de Vries W, Geutjes EJ, Prins M, de Haan P, Berkhout B. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog 2007; 3:86
   PubMed Web of Science ®Google Scholar
• Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, Bray M, et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003; 77:7945 - 7956
   PubMed Web of Science ®Google Scholar
• Hartman AL, Towner JS, Nichol ST. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 2004; 328:177 - 184
   PubMed Web of Science ®Google Scholar
• Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF, Honzatko RB, et al. Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci USA 2009; 106:411 - 416
   PubMed Web of Science ®Google Scholar
• Hartman AL, Dover JE, Towner JS, Nichol ST. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J Virol 2006; 80:6430 - 6440
   PubMed Web of Science ®Google Scholar
• Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan P, et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol 2010; 17:165 - 172
   PubMed Web of Science ®Google Scholar
• Hartman AL, Ling L, Nichol ST, Hibberd ML. Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol 2008; 82:5348 - 5358
   PubMed Web of Science ®Google Scholar
• Kash JC, Muhlberger E, Carter V, Grosch M, Perwitasari O, Proll SC, et al. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 2006; 80:3009 - 3020
   PubMed Web of Science ®Google Scholar
• Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid SP, et al. Mutations abrogating VP35 interaction with double-stranded RNA render ebola virus avirulent in guinea pigs. J Virol 2010; 84:3004 - 3015
   PubMed Web of Science ®Google Scholar
• Leung DW, Shabman RS, Farahbakhsh M, Prins KC, Borek DM, Wang T, et al. Structural and Functional Characterization of Reston Ebola Virus VP35 Interferon Inhibitory Domain. J Mol Biol 2010; 399:347 - 357
   PubMed Web of Science ®Google Scholar
• Kimberlin CR, Bornholdt ZA, Li S, Woods VL Jr, MacRae IJ, Saphire EO. Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc Natl Acad Sci USA 2010; 107:314 - 319
   PubMed Web of Science ®Google Scholar
• Cardenas WB, Loo YM, Gale M Jr, Hartman AL, Kimberlin CR, Martinez-Sobrido L, et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 2006; 80:5168 - 5178
   PubMed Web of Science ®Google Scholar
• Prins KC, Cardenas WB, Basler CF. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol 2009; 83:3069 - 3077
   PubMed Web of Science ®Google Scholar
• Reid SP, Cardenas WB, Basler CF. Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology 2005; 341:179 - 189
   PubMed Web of Science ®Google Scholar
• Johnson RF, McCarthy SE, Godlewski PJ, Harty RN. Ebola virus VP35-VP40 interaction is sufficient for packaging 3E-5E minigenome RNA into virus-like particles. J Virol 2006; 80:5135 - 5144
   PubMed Web of Science ®Google Scholar
• Becker S, Rinne C, Hofsass U, Klenk HD, Muhlberger E. Interactions of Marburg virus nucleocapsid proteins. Virology 1998; 249:406 - 417
   PubMed Web of Science ®Google Scholar
• Muhlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol 1999; 73:2333 - 2342
   PubMed Web of Science ®Google Scholar
• Feng Z, Cerveny M, Yan Z, He B. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol 2007; 81:182 - 192
   PubMed Web of Science ®Google Scholar
• Schumann M, Gantke T, Muhlberger E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol 2009; 83:8993 - 8997
   PubMed Web of Science ®Google Scholar
• Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 2006; 50:984 - 993
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010; 375:1896 - 1905
   PubMed Web of Science ®Google Scholar
• Chang TH, Kubota T, Matsuoka M, Jones S, Bradfute SB, Bray M, et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog 2009; 5:e1000493
   PubMed Web of Science ®Google Scholar
• Li X, Ranjith-Kumar CT, Brooks MT, Dharmaiah S, Herr AB, Kao C, et al. The RIG-I-like receptor LGP2 recognizes the termini of double-stranded NA. J Biol Chem 2009; 284:13881 - 13891
   PubMed Web of Science ®Google Scholar
• Prins KC, Binning JM, Shabman RS, Leung DW, Amarasinghe GK, Basler CF. Basic residues within the ebolavirus VP35 protein that are required for its viral polymerase cofactor function. J Virol 2010; 84:10581 - 10589
   PubMed Web of Science ®Google Scholar